EVALUASI PENGGUNAAN STRONGER NEO MINOPHAGEN C (SNMC) INJEKSI PADA GANGGUAN FUNGSI HATI DI BEBERAPA RUMAH SAKIT DI YOGYAKARTA
The use of Stronger Neo Minophagen C (SNMC) was studied in several hospitals in Yogyakarta. SNMC is an injection containing the active ingredient of glychyrrhizin which is derived from an herb and has long been used to treat liver function failure. This study is to determine the indications for SNMC...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Theses and Dissertations NonPeerReviewed |
| Published: |
[Yogyakarta] : Universitas Gadjah Mada
2013
|
| Subjects: | |
| Online Access: | https://repository.ugm.ac.id/123204/ http://etd.ugm.ac.id/index.php?mod=penelitian_detail&sub=PenelitianDetail&act=view&typ=html&buku_id=63315 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Institution: | Universitas Gadjah Mada |
| Summary: | The use of Stronger Neo Minophagen C (SNMC) was studied in several
hospitals in Yogyakarta. SNMC is an injection containing the active ingredient of
glychyrrhizin which is derived from an herb and has long been used to treat liver
function failure. This study is to determine the indications for SNMC and its
effects to the reduction of SGOT and SGPT.
This research was an observational study using a retrospective method on
medical records from hospital A, B, and C in Yogyakarta between the period of
January 1 to December 31, 2012. The subjects were all in-patients with the
inclusion criteria of receiving SNMC, SGOT > 40 IU/L, SGPT > 40 IU/L,
diagnosed with liver diseases (hepatitis A, B and C, liver cancer, cholestasis,
cholelitiasis, cholesistitis, choledocholithiasis, jaundice, fatty liver, and liver
abscess).
A total of 230 subjects were enrolled in this study, 141 cases of liver
disease and 89 cases of other diseases. From the 141 subjects, there were only 50
that fulfilled the inclusion criteria. Of the 50 patients, 12 were prescribed with
single SNMC and the rest received SNMC with other medications. The results
showed that single SNMC was able to decrease SGOT and SGPT by 18.05 to
93.62% and 9.31 to 77.55% respectively |
|---|